US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
US6518281B2
(en)
*
|
1995-08-29 |
2003-02-11 |
Celgene Corporation |
Immunotherapeutic agents
|
TW432073B
(en)
*
|
1995-12-28 |
2001-05-01 |
Pfizer |
Pyrazolopyridine compounds
|
US5635517B1
(en)
*
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
EP1361210B1
(en)
*
|
1996-08-12 |
2008-12-24 |
Celgene Corporation |
Novel immunotherapeutic agents and their use in the reduction of cytokine levels
|
US6673828B1
(en)
*
|
1998-05-11 |
2004-01-06 |
Children's Medical Center Corporation |
Analogs of 2-Phthalimidinoglutaric acid
|
US7629360B2
(en)
*
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
US6667316B1
(en)
*
|
1999-11-12 |
2003-12-23 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
US7182953B2
(en)
*
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
US6326388B1
(en)
|
1999-12-21 |
2001-12-04 |
Celgene Corporation |
Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
|
US6699899B1
(en)
*
|
1999-12-21 |
2004-03-02 |
Celgene Corporation |
Substituted acylhydroxamic acids and method of reducing TNFα levels
|
MXPA02009665A
(es)
*
|
2000-03-31 |
2005-09-08 |
Celgene Corp |
Inhibicion de actividad de ciclooxigenasa-2.
|
US8030343B2
(en)
|
2000-06-08 |
2011-10-04 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
WO2002064083A2
(en)
*
|
2000-11-30 |
2002-08-22 |
The Children's Medical Center Corporation |
Synthesis of 3-amino-thalidomide and its enantiomers
|
US7091353B2
(en)
*
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
US7491634B2
(en)
*
|
2006-04-28 |
2009-02-17 |
Asm International N.V. |
Methods for forming roughened surfaces and applications thereof
|
US7276529B2
(en)
*
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
US7208516B2
(en)
*
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
CN1965823B
(zh)
*
|
2002-03-20 |
2010-05-12 |
细胞基因公司 |
(+)-2-[1-(3-乙氧基-4-甲氧基苯基)-2-甲磺酰基乙基]-4-乙酰氨基异吲哚啉-1,3-二酮、其合成方法及其组合物
|
AU2003222034A1
(en)
*
|
2002-03-20 |
2003-10-08 |
Celgene Corporation |
(-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
US7498171B2
(en)
*
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
US20050118715A1
(en)
*
|
2002-04-12 |
2005-06-02 |
Hariri Robert J. |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
NZ536050A
(en)
|
2002-04-12 |
2007-11-30 |
Celgene Corp |
Methods of identifying modulators of angiogenesis using stem cells with the proviso the stems cells are not totipotent
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
US7393862B2
(en)
*
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
KR101059041B1
(ko)
*
|
2002-05-17 |
2011-08-24 |
셀진 코포레이션 |
암과 다른 질병의 치료 및 처리를 위한 선택적 사이토카인억제 약물을 사용하는 방법 및 조성물
|
DE60331537D1
(de)
*
|
2002-05-17 |
2010-04-15 |
Celgene Corp |
Kombinationen zur behandlung von multiplem myelom
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
WO2004004834A1
(en)
*
|
2002-07-02 |
2004-01-15 |
Qlt Inc. |
Compounds and methods for treating cancer and inflammation
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404716B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
MXPA05003889A
(es)
*
|
2002-10-15 |
2005-06-22 |
Celgene Corp |
Farmacos inhibidores de citosina selectiva para tratar sindrome mielodisplastico.
|
US20040087558A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
US7776907B2
(en)
*
|
2002-10-31 |
2010-08-17 |
Celgene Corporation |
Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
NZ540185A
(en)
*
|
2002-10-31 |
2008-01-31 |
Celgene Corp |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
|
TW200501945A
(en)
|
2002-11-06 |
2005-01-16 |
Celgene Corp |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
MXPA05004777A
(es)
*
|
2002-11-06 |
2005-07-22 |
Celgene Corp |
Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos.
|
BR0316256A
(pt)
*
|
2002-11-18 |
2005-10-04 |
Celgene Corp |
Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
|
EP1581205A1
(en)
*
|
2002-11-18 |
2005-10-05 |
Celgene Corporation |
Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
|
DE60330187D1
(de)
*
|
2002-12-30 |
2009-12-31 |
Celgene Corp |
Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
|
EP1601358B1
(en)
*
|
2003-03-03 |
2007-12-19 |
F. Hoffmann-La Roche Ag |
2,5-substituted tetrahydroisoquinolines for use as 5-ht6 modulators
|
BRPI0408113A
(pt)
*
|
2003-03-06 |
2006-03-01 |
Celgene Corp |
métodos para tratar ou prevenir um distúrbio do sistema nervoso central, para controlar um distúrbio do sistema nervoso central e para reduzir ou evitar um efeito adverso associado com a administração de um ingrediente ativo secundário em um paciente que sofre de um distúrbio do sistema nervoso central, e, composição farmacêutica
|
US20040175382A1
(en)
*
|
2003-03-06 |
2004-09-09 |
Schafer Peter H. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
|
BRPI0408223A
(pt)
*
|
2003-03-12 |
2006-03-01 |
Celgene Corp |
composto, isÈmeros, composição farmacêutica, e, métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa em um mamìfero e de tratar, previnir ou controlar uma doença ou condição
|
AU2004251717B2
(en)
*
|
2003-06-23 |
2010-03-11 |
Bellus Health (International) Limited |
Treatment of amyloid- and epileptogenesis-associated diseases
|
US7320992B2
(en)
*
|
2003-08-25 |
2008-01-22 |
Amgen Inc. |
Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
UA83504C2
(en)
*
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
CA2543132A1
(en)
*
|
2003-10-23 |
2005-05-19 |
Celgene Corporation |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
AP2006003637A0
(en)
*
|
2003-11-06 |
2006-06-30 |
Celgene Corp |
Methods and compositions using thalidomide for thetreatment and management of cancers and other diseases
|
US20050142104A1
(en)
*
|
2003-11-06 |
2005-06-30 |
Zeldis Jerome B. |
Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
|
NZ547689A
(en)
|
2003-11-19 |
2009-05-31 |
Signal Pharm Llc |
Indazole compounds and methods of use thereof as protein kinase inhibitors
|
WO2005055929A2
(en)
*
|
2003-12-02 |
2005-06-23 |
Celgene Corporation |
Methods and compositions for the treatment and management of hemoglobinopathy and anemia
|
AU2004319758A1
(en)
*
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
CN1972686A
(zh)
*
|
2004-04-14 |
2007-05-30 |
细胞基因公司 |
选择性细胞因子抑制药在髓发育不良综合征中的用途
|
AU2005234783A1
(en)
*
|
2004-04-23 |
2005-11-03 |
Celgene Corporation |
Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
|
AU2004319814A1
(en)
*
|
2004-05-05 |
2005-12-01 |
Celgene Corporation |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
|
US7244759B2
(en)
*
|
2004-07-28 |
2007-07-17 |
Celgene Corporation |
Isoindoline compounds and methods of making and using the same
|
US20070190070A1
(en)
*
|
2004-09-03 |
2007-08-16 |
Zeldis Jerome B |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
|
MX2007005040A
(es)
|
2004-10-28 |
2007-06-19 |
Celgene Corp |
Metodos y composiciones usando moduladores de pde4 para el tratamiento y manejo de lesion al sistema nervioso central.
|
JP2008523102A
(ja)
*
|
2004-12-13 |
2008-07-03 |
セルジーン・コーポレーション |
Pde4モジュレーターを含有する組成物及び気道炎症の治療又は予防のためのそれらの使用
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
TW200804347A
(en)
|
2006-01-10 |
2008-01-16 |
Janssen Pharmaceutica Nv |
Urotensin II receptor antagonists
|
CN101522197B
(zh)
|
2006-07-31 |
2013-12-11 |
詹森药业有限公司 |
尾加压素ⅱ受体拮抗剂
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
PA8782701A1
(es)
*
|
2007-06-07 |
2009-01-23 |
Janssen Pharmaceutica Nv |
Antagonistas del receptor de urotensina ii
|
US7893045B2
(en)
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
CN102036663A
(zh)
*
|
2008-03-24 |
2011-04-27 |
细胞基因公司 |
用环丙基-n-{2-[(1s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲磺酰基)乙基]-3-氧代异吲哚啉-4基}甲酰胺治疗银屑病或者银屑病关节炎
|
EP2687213B1
(en)
|
2008-03-27 |
2019-01-23 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
CA2718601A1
(en)
|
2008-03-27 |
2009-10-01 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
WO2010017105A1
(en)
*
|
2008-08-02 |
2010-02-11 |
Janssen Pharmaceutica N.V. |
Urotensin ii receptor antagonists
|
EP2334639B1
(en)
*
|
2008-09-10 |
2013-01-23 |
Celgene Corporation |
Processes for the preparation of aminosulfone compounds
|
PE20151143A1
(es)
|
2009-02-10 |
2015-08-07 |
Celgene Corp |
Metodos para utilizar y composiciones que comprenden moduladores pde4 para tratamiento, prevencion y control de tuberculosis
|
WO2010130224A1
(zh)
|
2009-05-14 |
2010-11-18 |
天津和美生物技术有限公司 |
噻吩衍生物
|
PL2443089T3
(pl)
*
|
2009-06-18 |
2014-09-30 |
Concert Pharmaceuticals Inc |
Deuterowane pochodne izoindolino-1,3-dionu jako inhibitory pde4 i tnf-alfa
|
MY183201A
(en)
|
2009-10-09 |
2021-02-18 |
Celgene Corp |
Processes for the preparation of 2-(1-phenylethyl)isoindolin-1-one compounds
|
JP5937060B2
(ja)
|
2010-04-07 |
2016-06-22 |
セルジーン コーポレイション |
呼吸器ウイルス感染症の治療方法
|
MX341896B
(es)
|
2010-06-15 |
2016-09-07 |
Celgene Corp * |
Biomarcadores para el tratamiento de psoriasis.
|
WO2012083153A1
(en)
*
|
2010-12-16 |
2012-06-21 |
Nektar Therapeutics |
Oligomer-containing apremilast moiety compounds
|
CN102558022B
(zh)
*
|
2010-12-22 |
2016-06-15 |
康塞特医药品有限公司 |
取代的异吲哚啉-1,3二酮衍生物
|
US8853175B2
(en)
|
2011-01-10 |
2014-10-07 |
Celgene Corporation |
Phenethylsulfone isoindoline derivatives and their use
|
WO2012097116A2
(en)
|
2011-01-14 |
2012-07-19 |
Celgene Corporation |
Isotopologues of isoindole derivatives
|
JP2014511393A
(ja)
|
2011-03-07 |
2014-05-15 |
セルジーン コーポレイション |
イソインドリン化合物を用いた疾患の治療方法
|
CA2834355A1
(en)
|
2011-04-28 |
2012-11-01 |
Celgene Corporation |
Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
|
SI2797581T1
(sl)
*
|
2011-12-27 |
2020-08-31 |
Amgen (Europe) GmbH |
Formulacije (+)-2-(1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil)- 4-acetil aminoizoindolin-1,3-diona
|
AR090100A1
(es)
*
|
2012-02-21 |
2014-10-22 |
Celgene Corp |
Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
|
EP2730278A1
(en)
|
2012-11-08 |
2014-05-14 |
Ratiopharm GmbH |
Composition melt
|
CN105050624A
(zh)
|
2013-03-14 |
2015-11-11 |
细胞基因公司 |
利用阿普斯特来治疗银屑病关节炎的方法
|
WO2014204825A1
(en)
|
2013-06-17 |
2014-12-24 |
Celgene Corporation |
Tablet formulations of (+)-2-[1 -(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
IN2014MU01283A
(da)
|
2014-04-04 |
2015-10-09 |
Cadila Healthcare Ltd |
|
WO2015173792A1
(en)
|
2014-05-11 |
2015-11-19 |
Mapi Pharma Ltd. |
Amorphous form of apremilast
|
EP3142748B1
(en)
|
2014-05-15 |
2019-09-11 |
Celgene Corporation |
Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis
|
WO2015175956A1
(en)
|
2014-05-16 |
2015-11-19 |
Celgene Corporation |
Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
|
EP2949645A1
(en)
|
2014-05-28 |
2015-12-02 |
LEK Pharmaceuticals d.d. |
Processes for the preparation of ß-aminosulfone compounds
|
ES2749433T3
(es)
|
2014-06-23 |
2020-03-20 |
Celgene Corp |
Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
|
EP3188745A1
(en)
|
2014-08-15 |
2017-07-12 |
Celgene Corporation |
Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
|
SI3182996T1
(sl)
|
2014-08-22 |
2023-04-28 |
Celgene Corporation |
Postopki zdravljenja multiplega mieloma z imunomodulatornimi spojinami v kombinaciji s protitelesi
|
CN105461610B
(zh)
*
|
2014-09-10 |
2018-04-13 |
杭州普晒医药科技有限公司 |
一种阿普斯特的晶型及其制备方法、药物组合物和用途
|
CN104761484B
(zh)
*
|
2014-11-24 |
2018-03-27 |
上海优拓医药科技有限公司 |
一种稳定的不含溶剂化物的阿普司特晶型ii及其制备方法
|
CN104496886A
(zh)
*
|
2014-12-11 |
2015-04-08 |
杭州新博思生物医药有限公司 |
一种高纯度阿普斯特b晶型的制备方法
|
CN107635962A
(zh)
|
2015-03-19 |
2018-01-26 |
印度商西伯拉有限公司 |
用于制备阿普斯特的改进工艺
|
EP3280701B1
(en)
|
2015-04-09 |
2019-10-16 |
Zentiva K.S. |
A method of chiral resolution of the key intermediate of the synthesis of apremilast and its use for the preparation of pure apremilast
|
WO2016169533A1
(en)
|
2015-04-24 |
2016-10-27 |
Zentiva, K.S. |
A solid form of apremilast and a process for preparing the same
|
US10370329B2
(en)
*
|
2015-04-27 |
2019-08-06 |
Mylan Laboratories Limited |
Process for the enantiomeric resolution of apremilast intermediates
|
CN104945306B
(zh)
*
|
2015-05-25 |
2017-07-21 |
山东铭康医药技术有限公司 |
制备光学纯阿普斯特的方法
|
CZ2015383A3
(cs)
|
2015-06-05 |
2016-12-14 |
Zentiva, K.S. |
Způsob přípravy klíčového intermediátu apremilastu, využívající enzymatické štěpení racemických aminů
|
EP3106457A1
(en)
|
2015-06-15 |
2016-12-21 |
LEK Pharmaceuticals d.d. |
A novel synthetic pathway towards apremilast
|
JP2018527302A
(ja)
|
2015-06-26 |
2018-09-20 |
セルジーン コーポレイション |
免疫調節化合物を用いたカポジ肉腫またはkshv誘発性リンパ腫の治療方法、及びバイオマーカーの使用
|
EP3144393A1
(en)
|
2015-09-18 |
2017-03-22 |
LEK Pharmaceuticals d.d. |
A synthetic pathway towards apremilast
|
WO2017059040A1
(en)
|
2015-09-29 |
2017-04-06 |
Pliva Hrvatska D.O.O. |
Processes for the preparation of apremilast and intermediates thereof
|
WO2017070291A1
(en)
|
2015-10-21 |
2017-04-27 |
Celgene Corporation |
Pde4 modulators for treating and preventing immune reconstitution inflammatory syndrome (iris)
|
WO2017085568A1
(en)
*
|
2015-11-19 |
2017-05-26 |
Alembic Pharmaceuticals Limited |
An improved process and novel polymorphic form of apremilast
|
CN105294533A
(zh)
*
|
2015-12-02 |
2016-02-03 |
宋彤云 |
一种治疗骨病的药物组合物
|
US10774041B2
(en)
|
2016-04-15 |
2020-09-15 |
Davuluri Ramamohan Rao |
Process for the preparation of apremilast
|
CN109310624A
(zh)
|
2016-06-15 |
2019-02-05 |
托伦特药物有限公司 |
阿普斯特的局部组合物
|
US10196355B2
(en)
|
2016-06-20 |
2019-02-05 |
Johnson Matthey Public Limited Company |
Forms of apremilast
|
CN106543050B
(zh)
*
|
2016-09-28 |
2018-04-10 |
中南大学湘雅医院 |
一种阿普斯特中间体的合成工艺
|
WO2018157779A1
(zh)
*
|
2017-02-28 |
2018-09-07 |
康朴生物医药技术(上海)有限公司 |
一种新的异二氢吲哚衍生物、其药物组合物及应用
|
US10689332B2
(en)
|
2017-04-04 |
2020-06-23 |
Quimica Sintetica, S.A. |
Racemic beta-aminosulfone compounds
|
EP3606908B1
(en)
|
2017-04-04 |
2020-06-17 |
Quimica Sintetica, S.A. |
Resolution of racemic beta-aminosulfone compounds
|
US10919855B2
(en)
|
2017-05-04 |
2021-02-16 |
Unichem Laboratories Ltd |
Process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4yl]acetamide
|
CN109422671B
(zh)
*
|
2017-08-31 |
2022-06-07 |
重庆医药工业研究院有限责任公司 |
一种阿普斯特中间体的制备方法
|
US20200254093A1
(en)
|
2017-09-14 |
2020-08-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
WO2019081235A1
(en)
|
2017-10-23 |
2019-05-02 |
Boehringer Ingelheim International Gmbh |
NEW ASSOCIATION OF ACTIVE AGENTS FOR THE TREATMENT OF PROGRESSIVE FIBROSANT INTERSTITIAL PNEUMOPATHY (PF-ILD)
|
WO2019142124A1
(en)
|
2018-01-17 |
2019-07-25 |
Cadila Healthcare Limited |
Pharmaceutical compositions for treatment of vitiligo
|
US20210139498A1
(en)
|
2018-05-02 |
2021-05-13 |
Tianjin Hemay Pharmaceutical Sci-Tech Co., Ltd |
Crystal forms of thiophene derivatives
|
CN110746376A
(zh)
*
|
2018-07-22 |
2020-02-04 |
上海星叶医药科技有限公司 |
苯并异硒唑酮胺类化合物及其制备方法和用途
|
CN110423213B
(zh)
*
|
2019-08-22 |
2021-06-04 |
上海英诺富成生物科技有限公司 |
一种阿普斯特衍生物及其制备方法与应用
|
EP3929179A1
(en)
|
2020-06-22 |
2021-12-29 |
Biohorm, S.L. |
Anti-inflammatory compounds and methods for their manufacture
|
CN114790164B
(zh)
|
2021-08-13 |
2022-12-27 |
苏州璞正医药有限公司 |
一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途
|